Parametric approaches towards understanding the effects of the preferential D3 receptor agonist pramipexole on prepulse inhibition in rats.
The preferential dopamine D3 receptor agonist pramipexole (PRA) disrupts prepulse inhibition (PPI) of acoustic startle, an operational measure of sensorimotor gating, in rats. Drug effects on PPI are sensitive to numerous experimental variables; proceeding with in-depth analyses of drug effects without a clear understanding of these variables is inefficient. The present studies characterized the impact on PRA-induced PPI deficits by a range of experimental parameters. As shown previously, PRA reduced both PPI and startle magnitude beginning 5-15 min post-injection; PRA effects on PPI were statistically significant through 35 min post-injection, while those on startle magnitude were still significant 65 min post-injection. PRA-induced PPI deficits were evident under conditions that matched startle magnitude in vehicle and PRA conditions and were independent of PRA-induced changes in prepulse-elicited motor activity. Additionally, PRA-induced PPI deficits did not differ significantly between uni- vs. cross-modal stimuli or between male vs. female rats, with no robust effect of estrous phase in females. These findings demonstrate that PRA effects on PPI are observed across several different experimental conditions and are dissociable from changes in startle magnitude or prepulse-elicited responses. Recommendations are made regarding "optimal" experimental conditions for studying the neurobiology of PRA-induced changes in PPI in rats.
Chang
Wei-li
WL
Department of Psychiatry, UCSD School of Medicine, La Jolla, CA 92093-0804, USA.
Swerdlow
Neal R
NR
Breier
Michelle R
MR
Thangaraj
Niveditha
N
Weber
Martin
M
D000161:Acoustic Stimulation; D000818:Animals; D052160:Benzothiazoles / Q000494:pharmacology*; D018491:Dopamine Agonists / Q000494:pharmacology*; D030762:Estrous Cycle; D005260:Female; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009433:Neural Inhibition / Q000187:drug effects*; D000077487:Pramipexole; D051381:Rats; D017207:Rats, Sprague-Dawley; D050637:Receptors, Dopamine D3 / Q000819:agonists*; D013216:Reflex, Startle / Q000187:drug effects; D055139:Sensory Gating / Q000187:drug effects; D012727:Sex Characteristics; D013997:Time Factors
D052160:Benzothiazoles; D018491:Dopamine Agonists; D050637:Receptors, Dopamine D3; D000077487:Pramipexole
Arch Gen Psychiatry. 1992 Mar;49(3):206-15
1567275
Psychoneuroendocrinology. 2008 Feb;33(2):178-87
18155361
Psychopharmacology (Berl). 1999 Sep;146(2):228-32
10525760
Psychopharmacology (Berl). 2009 Sep;205(4):689-98
19506839
J Neurosci. 1995 Mar;15(3 Pt 2):2301-11
7891168
Psychopharmacology (Berl). 2008 Aug;199(3):331-88
18568339
Biol Psychiatry. 1996 Jan 1;39(1):33-41
8719124
Psychopharmacology (Berl). 1990;102(1):1-4
2392496
Biol Psychiatry. 2001 Oct 15;50(8):578-85
11690592
Behav Neurosci. 2000 Apr;114(2):374-88
10832798
Psychopharmacology (Berl). 2004 Aug;174(4):452-62
15300359
Behav Pharmacol. 2005 Mar;16(2):127-30
15767849
Physiol Behav. 1998 Jul;64(5):625-8
9817573
Behav Brain Res. 1999 Oct;104(1-2):113-7
11125729
J Pharmacol Exp Ther. 2002 Nov;303(2):791-804
12388666
Neurosci Lett. 1996 Nov 22;219(2):138-40
8971799
Eur J Pharmacol. 1994 Oct 3;263(3):235-43
7843260
Pharmacol Biochem Behav. 2008 Jan;88(3):280-90
17936348
Behav Brain Res. 2009 Dec 7;204(2):387-95
19114060
Psychopharmacology (Berl). 1988;95(2):151-6
3137590
Behav Brain Res. 2009 Jun 8;200(1):165-72
19373982
Psychopharmacology (Berl). 1988;94(4):507-14
3131796
Braz J Biol. 2002 Nov;62(4A):609-14
12659010
J Neurosci. 1999 Jul 1;19(13):5644-53
10377370
Pharmacol Biochem Behav. 2009 Aug;93(2):141-7
19426754
Pharmacol Biochem Behav. 2008 Jan;88(3):306-11
17900675
Behav Pharmacol. 2008 Dec;19(8):786-95
19020413
J Neurosci Methods. 2008 Aug 30;173(2):295-8
18621080
Neuropsychopharmacology. 1998 Jan;18(1):50-6
9408918